Policy & Regulation
Takara Bio USA Launches Automated, Full-Length Single-Cell RNA-seq Solution for Enhanced Biomarker Discovery
19 October 2021 - - Japanese biotechnology company Takara Bio Inc's US-based Takara Bio USA, Inc subsidiary has launched the SMART-Seq Pro kit for the ICELL8 cx Single-Cell System, the company said.

This automated single-cell RNA-seq solution allows scientists to generate full-length transcriptome data from over 1,500 single cells simultaneously and from a wide range of sample types, even large, delicate adult cardiomyocytes.

While single-cell RNA sequencing has exploded in popularity over the last 10 years, two significant challenges remain: maintaining the sensitivity of the assay during miniaturization and interrogating full-length mRNA transcripts for potential biomarkers.

The ICELL8 cx Single-Cell System is an advanced, integrated automation platform for imaging and dispensing thousands of single cells in 5,184-nanowell chips.

With the launch of the SMART-Seq Pro kit for the ICELL8 cx system, Takara Bio USA has created an end-to-end solution for sensitive transcriptome analysis of up to eight samples at once.

With the integrated Cogent Analysis Pipeline and Cogent Discovery software, scientists can analyze their samples for rare biomarkers like isoforms, gene fusions, and single nucleotide variants, which are missed with other systems.

Takara Bio USA, Inc. is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.

Takara Bio offers a host of life science research solutions, from enzymes and GMP reagents to contracted cell and gene therapy manufacturing services, and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols.


Related Headlines